Konis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 17-11-2024
- Paid Up Capital ₹ 2.00 M
as on 17-11-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.48 Cr
as on 17-11-2024
- Revenue 28.07%
(FY 2023)
- Profit -36.12%
(FY 2023)
- Ebitda -14.33%
(FY 2023)
- Net Worth 3.61%
(FY 2023)
- Total Assets 11.40%
(FY 2023)
About Konis Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹1.48 Cr.
Jhansi Seelam and Rama Seelam serve as directors at the Company.
- CIN/LLPIN
U24230HP2005PTC028351
- Company No.
028351
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2005
- Date of AGM
14 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- LocationTeh. & Distt Solan Hp, Himachal Pradesh
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Konis Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jhansi Seelam  | Director | 31-Jul-2020 | Current |
| Rama Seelam | Director | 07-Mar-2022 | Current |
Financial Performance of Konis Pharmaceuticals.
Konis Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.07% increase. The company also saw a substantial fall in profitability, with a 36.12% decrease in profit. The company's net worth moved up by a moderate rise of 3.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Konis Pharmaceuticals?
In 2023, Konis Pharmaceuticals had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 Sep 2023 | ₹3.04 M | Open |
Hdfc Bank Limited Creation Date: 22 Mar 2022 | ₹1.79 M | Open |
Punjab National Bank Creation Date: 14 Mar 2006 | ₹1.00 Cr | Open |
How Many Employees Work at Konis Pharmaceuticals?
Konis Pharmaceuticals has a workforce of 20 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Konis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Konis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
